← Back to Screener
GT Biopharma Inc. Common Stock (GTBP)
Price$0.38
Favorite Metrics
Price vs S&P 500 (26W)-56.54%
Price vs S&P 500 (4W)-28.89%
Market Capitalization$11.72M
All Metrics
Book Value / Share (Quarterly)$0.23
P/TBV (Annual)52.56x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.51
Price vs S&P 500 (YTD)-56.64%
Gross Margin (TTM)36.51%
Net Profit Margin (TTM)-26209.52%
EPS (TTM)$-10.78
10-Day Avg Trading Volume0.51M
EPS Excl Extra (TTM)$-10.78
EPS (Annual)$-6.94
Dividend / Share (Annual)$0.02
ROI (Annual)-101.62%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-26774.13%
Cash / Share (Quarterly)$0.27
ROA (Last FY)-311.01%
EBITD / Share (TTM)$-9.40
ROE (5Y Avg)-569.56%
Operating Margin (TTM)-8623.81%
Cash Flow / Share (Annual)$-0.51
P/B Ratio2.02x
P/B Ratio (Quarterly)1.44x
Net Income / Employee (Annual)$-13
EV / Revenue (TTM)77.86x
Net Interest Coverage (TTM)-80.82x
ROA (TTM)-576.41%
EPS Incl Extra (Annual)$-6.94
Current Ratio (Annual)3.50x
Quick Ratio (Quarterly)3.25x
3-Month Avg Trading Volume1.26M
52-Week Price Return-83.64%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.24
P/S Ratio (Annual)433.92x
Asset Turnover (Annual)0.50x
52-Week High$3.85
Operating Margin (5Y Avg)-10668.30%
EPS Excl Extra (Annual)$-6.94
26-Week Price Return-49.65%
Quick Ratio (Annual)3.25x
13-Week Price Return-49.14%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.50x
Enterprise Value$4.905
Asset Turnover (TTM)0.08x
Book Value / Share Growth (5Y)-84.55%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.71x
Pretax Margin (Annual)-79485.19%
Cash / Share (Annual)$0.27
3-Month Return Std Dev85.51%
Gross Margin (5Y Avg)26.61%
Net Income / Employee (TTM)$-26
ROE (Last FY)-101.62%
Net Interest Coverage (Annual)-10.95x
EPS Basic Excl Extra (Annual)$-6.94
P/FCF (TTM)1065.09x
Receivables Turnover (TTM)3.05x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-10.78
Receivables Turnover (Annual)3.05x
ROI (TTM)276.63%
P/S Ratio (TTM)185.97x
Pretax Margin (5Y Avg)-26782.80%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.36
Price vs S&P 500 (52W)-118.28%
Year-to-Date Return-52.71%
5-Day Price Return-4.55%
EPS Normalized (Annual)$-6.94
ROA (5Y Avg)-233.96%
Net Profit Margin (Annual)-79485.19%
Month-to-Date Return-9.02%
Cash Flow / Share (TTM)$-0.27
EBITD / Share (Annual)$-7.15
Operating Margin (Annual)-33062.96%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-352.25%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-10.78
P/TBV (Quarterly)52.56x
P/B Ratio (Annual)1.44x
Inventory Turnover (TTM)2.71x
Pretax Margin (TTM)-26238.10%
Book Value / Share (Annual)$0.23
Price vs S&P 500 (13W)-51.52%
Beta0.78x
P/FCF (Annual)34.26x
Revenue / Share (TTM)$0.00
ROE (TTM)276.63%
52-Week Low$0.35
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GTBPGT Biopharma Inc. Common Stock | 185.97x | — | 36.51% | — | $0.38 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $899.91 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $224.87 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $205.74 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $112.62 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $196.15 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $148.70 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $38.87 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $94.12 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.37 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $58.80 |
About
GT Biopharma is a clinical-stage biopharmaceutical company developing immuno-oncology drugs using its proprietary TriKE platform. The platform's therapeutic candidates are designed to treat hematologic malignancies, sarcoma, and solid tumors. The company is advancing these novel therapies toward commercialization in the U.S.